T-CELL LYMPHOMA

This is an early-stage safety study for a new type of personalized cell therapy called CD4CAR. It is for adults and teens (12+) with T-cell leukemia or lymphoma that has come back or not responded to standard treatments. Doctors will collect a patient's own immune cells, genetica…

This study is testing if a drug called ruxolitinib can help patients with T-cell lymphoma stay in remission after a stem cell transplant. The drug is taken daily for a year to try to prevent the cancer from coming back and to reduce a dangerous complication where the donor cells …

This study is testing whether the drug enasidenib is a safe and effective treatment for adults with a rare and aggressive type of blood cancer called angioimmunoblastic T-cell lymphoma (AITL) that has a specific genetic change (IDH2 mutation). Researchers will give enasidenib eit…

This is an early-stage trial testing a new drug called BI-1808 for people with advanced cancers that have stopped responding to standard treatments. The main goals are to find a safe dose and see how well the body tolerates the drug, both by itself and when combined with an exist…

This is an early-stage study testing a new intravenous drug called ST-001 for people with T-cell lymphoma that has come back or not responded to prior treatments. The main goals are to find the highest safe dose and understand how the drug works in the body. It is for adults whos…

This study is testing whether adding a drug called mogamulizumab to standard chemotherapy works better for aggressive T-cell lymphoma. Researchers will enroll 22 adults with newly diagnosed or returning lymphoma to see if this combination leads to complete remission. The goal is …

This study is testing whether adding one of two targeted drugs, dasatinib or venetoclax, to standard chemotherapy can help children and young adults with newly diagnosed T-cell leukemia or lymphoma. The goal is to see if these additions lead to better early results and improve su…

This early-stage study is testing the safety and best dose of an oral medication called tazemetostat for adults with peripheral T-cell lymphoma that has returned or not responded to prior treatment. The drug is already approved for a different type of lymphoma. Researchers will e…

This study aims to understand how children's bodies process a liquid form of the cancer drug venetoclax, which is made by crushing tablets. It involves 30 children and young adults with blood cancers who cannot swallow pills and are already receiving this liquid medicine as part …